Key Considerations: How CDMOs Can Maximize Productivity And Scalability

By Kevin Mullen, Jason Lukasek, and Jonathan Foster, Thermo Fisher Scientific

Flexibility is key to successful operation in this quickly evolving paradigm, fueling increased industry reliance on contract development and manufacturing organizations (CDMOs).  A recent BioPlan Associates, Inc., survey identified outsourcing growth, the need for bioprocessing production flexibility, supply chain diversification, and increased leverage of single-use systems as trends that will drive biopharmaceutical R&D and manufacturing in 2021 and beyond. To meet industry demand for these capabilities, CDMOs must grow and evolve, scaling up through innovative workflows — without sacrificing product quality or speed to market.